期刊
THROMBOSIS AND HAEMOSTASIS
卷 110, 期 4, 页码 681-688出版社
GEORG THIEME VERLAG KG
DOI: 10.1160/TH12-12-0928
关键词
Obesity; antiplatelets; anticoagulants
资金
- Spanish Ministry of Science [PNS2010-16549 1]
- Spanish Ministry of Science and Innovation (MICINN) [RyC-2009-5495]
- [CIBEROBN06]
Clinical management of obese subjects to reduce their risk of suffering cardiovascular events is complex. Obese patients typically require preventive strategies, life-style modifications, and multi-drug therapy to address obesity-induced co-morbidities. Data regarding the effects of excess weight on the pharmacokinetics of most drugs is scarce as these individuals are often excluded from clinical trials. However, the physiological alterations observed in obese patients and their lower response to some antiplatelet agents and anticoagulants have suggested that dosage regimes need to be adjusted for these subjects. In this review we will briefly discuss platelet alterations that can contribute to increased thrombotic risk, analyse existing data regarding, the effects of obesity on drug pharmacokinetics focusing on antiplatelet agents and anticoagulants, and we will describe the beneficial effects of weight loss on thrombosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据